Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case-Control Study.
LED
Parkinson's disease
Rasagiline
levodopa equivalent dose
safinamide
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
09
12
2022
accepted:
21
01
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
epublish
Résumé
Effects of dopaminergic medications used to treat Parkinson's disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (LED). However, current LED proposals on MAO-B inhibitors (iMAO-B) safinamide and rasagiline are still based on empirical approaches. To estimate LED of safinamide 50 and 100 mg. In this multicenter, longitudinal, case-control study, we retrospectively reviewed clinical charts of 500 consecutive PD patients with motor complications and treated with (i) safinamide 100 mg ( Major baseline features (age, sex, disease duration and stage, severity of motor signs and motor complications) were similar among the groups. Patients on rasagiline had lower UPDRS-II scores and Levodopa dose than control subjects. After a mean follow-up of 8.8-to-10.1 months, patients on Safinamide 50 mg and 100 mg had lower UPDRS-III and OFF-related UPDRS-IV scores than control subjects, who in turn had larger increase in total LED than the three iMAO-B groups. After adjusting for age, disease duration, duration of follow-up, baseline values and taking change in UPDRS-III scores into account (sensitivity analysis), safinamide 100 mg corresponded to 125 mg LED, whereas safinamide 50 mg and rasagiline 1 mg equally corresponded to 100 mg LED. We used a rigorous approach to calculate LED of safinamide 50 and 100 mg. Large prospective pragmatic trials are needed to replicate our findings.
Sections du résumé
Background
UNASSIGNED
Effects of dopaminergic medications used to treat Parkinson's disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (LED). However, current LED proposals on MAO-B inhibitors (iMAO-B) safinamide and rasagiline are still based on empirical approaches.
Objectives
UNASSIGNED
To estimate LED of safinamide 50 and 100 mg.
Methods
UNASSIGNED
In this multicenter, longitudinal, case-control study, we retrospectively reviewed clinical charts of 500 consecutive PD patients with motor complications and treated with (i) safinamide 100 mg (
Results
UNASSIGNED
Major baseline features (age, sex, disease duration and stage, severity of motor signs and motor complications) were similar among the groups. Patients on rasagiline had lower UPDRS-II scores and Levodopa dose than control subjects. After a mean follow-up of 8.8-to-10.1 months, patients on Safinamide 50 mg and 100 mg had lower UPDRS-III and OFF-related UPDRS-IV scores than control subjects, who in turn had larger increase in total LED than the three iMAO-B groups. After adjusting for age, disease duration, duration of follow-up, baseline values and taking change in UPDRS-III scores into account (sensitivity analysis), safinamide 100 mg corresponded to 125 mg LED, whereas safinamide 50 mg and rasagiline 1 mg equally corresponded to 100 mg LED.
Conclusions
UNASSIGNED
We used a rigorous approach to calculate LED of safinamide 50 and 100 mg. Large prospective pragmatic trials are needed to replicate our findings.
Identifiants
pubmed: 37070060
doi: 10.1002/mdc3.13681
pii: MDC313681
pmc: PMC10105110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
625-635Informations de copyright
© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Parkinsonism Relat Disord. 2020 Jun;75:17-23
pubmed: 32446176
Biomolecules. 2021 Apr 20;11(4):
pubmed: 33924103
N Engl J Med. 2013 Feb 14;368(7):610-22
pubmed: 23406026
Mov Disord. 2011 May;26(6):1072-82
pubmed: 21626552
CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):611-621
pubmed: 33939329
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Mov Disord. 2011 Mar;26(4):587-98
pubmed: 21370258
Mov Disord. 2014 Feb;29(2):229-37
pubmed: 24323641
J Parkinsons Dis. 2020;10(1):173-178
pubmed: 31868682
Fundam Clin Pharmacol. 2021 Jun;35(3):620-630
pubmed: 33458868
Eur J Neurol. 2013 Feb;20(2):271-80
pubmed: 22967035
Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23
pubmed: 17030736
Mov Disord. 2012 Jan;27(1):106-12
pubmed: 21913224
Brain. 2009 Nov;132(Pt 11):2947-57
pubmed: 19759203
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Neurol Res Pract. 2021 Oct 25;3(1):58
pubmed: 34689840
Neurology. 2000 Aug 22;55(4):539-44
pubmed: 10953188
JAMA Neurol. 2017 Feb 01;74(2):216-224
pubmed: 27942720
Brain. 2014 Oct;137(Pt 10):2731-42
pubmed: 25034897
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345
pubmed: 32258239
J Neurol. 2017 Jun;264(6):1254-1263
pubmed: 28550482
Mov Disord. 2014 Sep;29(10):1273-80
pubmed: 25044402